Manage BPPV (Benign Paroxysmal Positional Vertigo) with effective first-line treatments like the Epley Maneuver, a non-invasive technique to reposition displaced otoconia, offering up to 90% success. Consider supervised maneuvers or Vestibular Rehabilitation Therapy (VRT) for recurrent or persistent symptoms. Medications like meclizine or diazepam are reserved for severe cases to alleviate nausea or anxiety.
January 9, 2025

BPPV (Benign Paroxysmal Positional Vertigo)

Evidence-Based Over-the-Counter Guide

William Shen

William Shen

Co-founder & CPO

See all guides. Have more questions?

BPPV is caused by displaced calcium carbonate crystals (otoconia) within the inner ear. This displacement disrupts normal vestibular function and leads to dizziness or vertigo with changes in head position.

First-line recommendations:

  • Canalith Repositioning Maneuvers (Epley Maneuver): These are non-invasive techniques that reposition the displaced otoconia back to their proper location in the inner ear. Up to 80–90% success rate. Performed as needed until symptoms resolve. Epley Maneuver self-tutorial

Physical therapy:

  • Supervised Repositioning Maneuvers: Since doing the maneuver properly can be highly uncomfortable, supervision of a healthcare provider or trained physical therapist may be necessary.

  • Vestibular Rehabilitation Therapy (VRT): Exercises focused on improving balance and compensating for inner ear dysfunction. Recommended for patients with recurrent BPPV or persistent symptoms.

Prescription medications:

Medications are generally not recommended for BPPV but may be used in severe cases to manage symptoms such as nausea or anxiety. Examples include:

  • Meclizine (antihistamine): Orally as needed for vertigo.

  • Diazepam (benzodiazepine): Orally as needed for severe symptoms (prescription required).

Citation:

Bhattacharyya N, Gubbels SP, Schwartz SR, et al. Clinical Practice Guideline: Benign Paroxysmal Positional Vertigo (Update). Otolaryngol Head Neck Surg. 2017; 156(3_suppl): p.S1-S47. doi: 10.1177/0194599816689667

What OTC evidence is reviewed?

  • For each condition, we performed a literature review to find a recent widely cited expert group guideline published in the leading specialty-specific peer-reviewed journal or top general medical journal.

  • Based on the recommendations in the publication, we identify recommended active ingredients and devices that are available over-the-counter per FDA regulations.

What evidence is prioritized?

Levels of evidence considered:

  • Tier 1 (Safe and Definitely Effective): Professional field consensus or multiple randomized controlled clinical trials showing the same conclusion. Wherever possible, we use Tier 1 evidence for "first-line" recommendations.

  • Tier 2 (Safe and Probably Effective): Individual clinical trials which may be discordant or large-scale observational experience. Tier 2 evidence may inform "first-line", "second-line", or "supplement" recommendations.

  • Tier 3 (Safe and Maybe Effective): Mechanistic plausibility without high-quality clinical evidence of efficacy but high-quality evidence of safety. Tier 3 evidence may inform "second-line" or "supplement" recommendations.

How does MDandMe select recommended products?

  • Based on the top clinical recommendation, we evaluate products containing the recommended active agent with FDA-approved dosage based on price, average customer reviews, how often it is purchased, and how quickly it will ship to home. 

  • We provide public documentation of the active ingredients in our recommendations, using all 32 FDA monographs, Prescription-to-Nonprescription (Rx-to-OTC) Switches, as well as New Drug Application (NDA) approvals.

How does MDandMe select recommended devices?

  • Based on the top clinical recommendation, we evaluate devices that are FDA-cleared or comply with other medical guidelines (if not a FDA-regulated category) by reputability, price, and average customer reviews.

  • We provide public documentation of supporting evidence for each device.